CFDA has submitted the proposal to the State Council for approval. The proposed policy changes include: establishing a Marketing Authorization Holder system for innovative drugs and a special review mechanism for innovative drugs; changing the review strategy for generic drugs; eliminating separate review for pharmaceutical excipients and packaging materials; and adjusting application fee schedules.
Several possible changes are of particular importance to life sciences and pharmaceutical companies. Eligibility for special review (so-called “Green Channel” or accelerated review) may be expanded to include imported innovative drugs if manufacturing is transferred to domestic production, pediatric drugs, and innovative products with new and advanced formulation technology or significant therapeutic benefits. In addition, the Chinese Center for Drug Evaluation may strengthen the criteria for application acceptance and gradually require universal use of the Common Technical Document in applications. On-site inspections of manufacturing facilities and clinical trials are also likely to increase.
Specific measures will be announced and implemented throughout 2015. Life sciences companies should closely monitor CFDA’s policy and procedure changes and update their regulatory plans accordingly.
If you have any questions regarding this Sidley Update, please contact the Sidley lawyer with whom you usually work, or
|Chen Yang, Partner||Ling Su, Strategic Advisor|
Sidley China Life Sciences Practice
To receive Sidley Updates, please subscribe at www.sidley.com/subscribe.
Sidley Austin provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship.
Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212.839.5300; One South Dearborn, Chicago, IL 60603, 312.853.7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202.736.8000.